Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET
暂无分享,去创建一个
Richard Pötter | Wolfgang Wadsak | Markus Mitterhauser | Marcus Hacker | Thomas Helbich | Georgios Karanikas | Dietmar Georg | Katja Pinker | P. Georg | R. Pötter | D. Georg | T. Helbich | W. Wadsak | M. Mitterhauser | G. Karanikas | P. Baltzer | M. Hacker | K. Pinker | P. Andrzejewski | Petra Georg | Piotr Andrzejewski | Pascal Baltzer | Michaela Daniel | Alina Sturdza | Katarina Majercakova | M. Daniel | A. Sturdza | K. Majercakova | R. Pötter
[1] Michael Baumann,et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[2] Heidi Lyng,et al. Pharmacokinetic parameters derived from dynamic contrast enhanced MRI of cervical cancers predict chemoradiotherapy outcome. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[3] M. Mix,et al. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[4] Ciprian Catana,et al. Simultaneous PET-MRI in oncology: a solution looking for a problem? , 2012, Magnetic resonance imaging.
[5] M. Schwaiger,et al. Quantitative Analysis of [18F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry , 2017, Molecular Imaging and Biology.
[6] A. W. Simonetti,et al. Assessment of early response to concurrent chemoradiotherapy in cervical cancer: value of diffusion-weighted and dynamic contrast-enhanced MR imaging. , 2014, Magnetic resonance imaging.
[7] Steen Jakobsen,et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[8] Richard Pötter,et al. MRI Assessment of Cervical Cancer for Adaptive Radiotherapy , 2009, Strahlentherapie und Onkologie.
[9] Wade P. Smith,et al. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] Christian Kirisits,et al. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. , 2005, International journal of radiation oncology, biology, physics.
[11] John M Buatti,et al. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. , 2002, International journal of radiation oncology, biology, physics.
[12] K Thielemans,et al. Image-based point spread function implementation in a fully 3D OSEM reconstruction algorithm for PET , 2010, Physics in medicine and biology.
[13] Christian Kirisits,et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[14] M. Picchio,et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[15] W Zhen,et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer , 2000, Journal of magnetic resonance imaging : JMRI.
[16] Johannes A Langendijk,et al. PET Imaging of Tumor Hypoxia Using 18F-Fluoroazomycin Arabinoside in Stage III–IV Non–Small Cell Lung Cancer Patients , 2013, The Journal of Nuclear Medicine.
[17] Dae Hyuk Moon,et al. Fully automated synthesis of [18F]fluoromisonidazole using a conventional [18F]FDG module. , 2005, Nuclear medicine and biology.
[18] R. Steenbakkers,et al. PET-based analysis of tumor glucose metabolism and tumor hypoxia before and during anti-neoplastic treatment , 2015 .
[19] N. deSouza,et al. Diffusion-weighted magnetic resonance imaging and its application to cancer , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.
[20] M. Schwaiger,et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.
[21] Jian Z. Wang,et al. Predicting Control of Primary Tumor and Survival by DCE MRI During Early Therapy in Cervical Cancer , 2009, Investigative radiology.
[22] Young-Bin Cho,et al. Cervical cancer regression measured using weekly magnetic resonance imaging during fractionated radiotherapy: radiobiologic modeling and correlation with tumor hypoxia. , 2008, International journal of radiation oncology, biology, physics.
[23] Werner Vach,et al. Serial [18F]-fluoromisonidazole PET during radiochemotherapy for locally advanced head and neck cancer and its correlation with outcome. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[24] T. Yankeelov,et al. Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer , 2017, Molecular Imaging and Biology.
[25] Jian Z. Wang,et al. Ultra‐early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer , 2010, Cancer.
[26] Søren M Bentzen,et al. Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.
[27] K. Hamacher,et al. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] Richard Pötter,et al. Evaluating repetitive 18F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer , 2010, Acta oncologica.
[29] Andras Lasso,et al. SlicerRT: radiation therapy research toolkit for 3D Slicer. , 2012, Medical physics.
[30] P. Pauwels,et al. Baseline [18F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model , 2016, Molecular Imaging and Biology.
[31] B. K. Park,et al. Parametrial invasion in cervical cancer: fused T2-weighted imaging and high-b-value diffusion-weighted imaging with background body signal suppression at 3 T. , 2015, Radiology.
[32] R. Steenbakkers,et al. Head and Neck Tumor Hypoxia Imaging by 18F-Fluoroazomycin-arabinoside (18F-FAZA)-PET: A Review , 2014, Clinical nuclear medicine.
[33] Helmar Bergmann,et al. PET based volume segmentation with emphasis on the iterative TrueX algorithm. , 2012, Zeitschrift fur medizinische Physik.
[34] Takeo Ishigaki,et al. Apparent diffusion coefficient in cervical cancer of the uterus: comparison with the normal uterine cervix , 2004, European Radiology.
[35] Wolfgang Wadsak,et al. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study , 2016, PloS one.